Safety updates
A safety update gives practical information relating to the safety of a medicine or medical device (therapeutic product), including emerging safety issues. These updates are provided for health professionals.
Medicine safety updates
Our Medicine safety update (MSU) articles provide health professionals with practical information and advice on medicine safety, including emerging safety issues. We publish these articles as the safety issues occur (see links to the latest safety updates below).
As well as these detailed articles, we publish a monthly list of Product Information safety updates. This summarises significant changes relating to medicine safety for health professionals.
Product Information safety updates
Anyone can subscribe and receive email notifications when new articles are published.
Medical devices safety updates
Medical Devices Safety Update (MDSU) provides health professionals with practical information and advice on medical device safety and information about emerging safety issues.
The articles provide information on adverse event reporting and how health professionals can contribute to safety monitoring in Australia.
Safety update articles are published as relevant topics arise.
Health professionals and interested persons can subscribe and receive email notifications when new articles are published.
Latest Safety updates
-
Health care professionals should check product-specific instructions when preparing and administering vaccines.
-
We are reviewing new information that has raised concerns regarding the integrity and reliability of the clinical trial data that supported the approval of TAVNEOS (avacopan) in Australia.
-
Product warnings across the glucagon-like-peptide-1 receptor agonist (GLP-1 RA) class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder.
-
Cases of liver injury associated with herbal preparations containing Withania somnifera, commonly known as Ashwagandha, continue to be reported both in Australia and internationally.
-
We have identified reports of FluMist being administered in error to children under 2 years of age.
-
Cases of medication errors have been identified internationally where tranexamic acid injection was inadvertently administered to the spinal cord, resulting in severe pain, seizures, cardiac arrhythmias and deaths.